Hepion pharmaceuticals announces early completion of enrollment in phase 2 ‘altitude-nash' liver function trial

– hepion enrolls 60 f3 nash subjects in only 12 weeks, facilitated by agile 3+ non-invasive test –
HEPA Ratings Summary
HEPA Quant Ranking